Contrôle qualité des médicaments à base d'Ibuprofène commercialisés à Maradi (Niger)
- ijppna
- 11 juil.
- 2 min de lecture
Dernière mise à jour : 9 août
Bahari KASSOUM DJATAOU 1*, Mahamadou OUDOU MOSSI MAIGA 2, Moustapha ABDOULAYE GAMBO2, Fatima GUIET MATI 2, Saratou SAMINOU 1, Libabatou IBRAHIM ZANGUINA2, Abdoul Kadir IBRAHIM MAMADOU 3, Daouda ALHOUSSEINI 2, Ousmane ABDOULAYE 1,4, MAMAN SANI FALISSOU Saidou1, Barira DAN NOUHOU 5, Rakia BAGOUDOU 6, Chaibou SALAOU 7, Boutchi MOUNKAILA 2
1 : Faculté des Sciences de la Santé ; Université Dan Dicko Dankoulodo de Maradi (FSS/UDDM), Niger
2 : Faculté des Sciences de la Santé ; Université Abdou Moumouni de Niamey (FSS/UAM), Niger
3 : Hôpital de Référence de Maradi (HRM), Niger
4 : Laboratoire National de Santé Publique et d’Expertise (LANSPEX), Niger
5 : Nigérienne des Industries Pharmaceutiques (NIPHAR)
6 : Direction des Pharmacies et de la Médecine Traditionnelle (DPH/MT), Niger
7 : Office National des Produits Pharmaceutiques et Chimiques (ONPPC), Niger
*Correspondance:bahari.kassoum@uddm.edu.ne
DOI: 10.61585/pud-IJPPNA-v4i102
Abstract: Substandard and falsified medicines (SFM) pose a growing public health threat in sub-Saharan Africa. Maradi, Niger's main commercial hub bordering Nigeria, faces heightened exposure to this risk. Ibuprofen, a widely self-medicated non-steroidal anti-inflammatory drug, is distributed through heterogeneous, poorly controlled supply chains. The objective of this study was to assess the pharmaceutical quality of ibuprofen-based medicines marketed in Maradi.
This work is a cross-sectional analytical study (October 2023 – May 2024, LANSPEX). Twenty-five samples (16 tablets 400 mg, 9 oral suspensions 200 mg/mL) were collected by stratified random sampling from formal (n=18) and informal (n=7) sectors. Analyses followed European Pharmacopoeia. 9.0 and United State Pharmacopoeia 43-National Formular38 monographs.
Of 25 samples, 14 (56.0 %) were compliant and 11 (44.0 %) non-compliant, predominantly underdosed (90.9%). Oral suspensions showed higher non-compliance rates than tablets (77.8 % vs 25.0 %, p=0.017). The informal sector concentrated 62.5 % of NC (vs 11.1%, p=0.033). Origin continent was significantly associated with compliance (p=0.029). Nigeria showed 100 % NC (5/5).
A 44% non-compliance rate underscores the urgent need to strengthen pharmaceutical market surveillance in Maradi, particularly at borders and within informal distribution networks.
Keywords: substandard medicines, informal market, non-steroidal anti-inflammatory.
Graphical abstract
Commentaires